A randomized controlled trial will test the feasibility of adding behavioral activation therapy (BAT) to oral ketamine for treatment-resistant major depressive disorder. The study aims to recruit 60 adults aged 18–65 years, randomizing them to eight weeks of oral ketamine with BAT or oral ketamine alone. Feasibility will be measured by attendance, acceptability, and retention. The primary efficacy outcome is the Montgomery-Asberg Depression Rating Scale, assessed weekly during treatment and fortnightly during 12 weeks of follow-up. For a definitive trial to be recommended, the study must meet recruitment targets and show a greater than 20% reduction in relapse rates favoring the combined treatment arm.
Anxiety and depression are common in people with COPD, worsening disability and reducing quality of life. The anxiety-breathlessness cycle and low self-efficacy hinder self-management. Standard mindfulness programs help but require travel and time. This mixed-method pre-post study with 3-month follow-up tests the feasibility of a portable, self-delivered mindful breathing intervention for up to 30 adults with COPD in New Zealand. Primary aims are uptake, retention, adherence, and acceptability; secondary aims include preliminary change in self-efficacy. Data collection is ongoing. If feasible, the intervention could reduce barriers to treatment and support a larger trial.